Navigation Links
Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever
Date:11/2/2010

cluding, without limitation: our dependence on the successful commercialization of OFIRMEV; the potential that we will require substantial additional funding in order to effectively commercialize OFIRMEV, and the risk that we may not be able to raise sufficient capital when needed, or at all; the risk that delays in commercially launching OFIRMEV would enable competitors to further entrench their existing products or develop and bring new products to market before OFIRMEV; our ability to ensure an adequate and continued supply of OFIRMEV to successfully launch commercial sales or meet anticipated market demand; our ability to comply with the terms of our loan agreement, and draw down additional amounts under our loan agreement; the potential for an event of default under our loan agreement, and the corresponding risk of acceleration of repayment and potential foreclosure on the assets pledged to secure the line of credit; the impact of healthcare reform legislation; and other risks detailed in Cadence's prior press releases as well as in Cadence's periodic public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Cadence™ and OFIRMEV™ are trademarks of Cadence Pharmaceuticals, Inc.  Contacts:INVESTORS

MEDIACadence Pharmaceuticals, Inc.

WCGWilliam R. LaRue, SVP and Chief Financial Officer

Hayley Soffer858-436-1400

212-301-7176blarue@cadencepharm.com

hsoffer@w
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
2. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
8. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
9. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
10. Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... September 30, 2014.  Biorem,s complete 2014 third quarter financial statements and ... Financial Summary:Three-months ended September 30, , Nine-months ended ... , 2014 , 2013 , 2014 ... 5,281 , 6,715 , 14,476 Gross profit ...
(Date:11/18/2014)... 2014 Athena Signature Series: Turning Cancer ‘Off’ ... Emerson, a professor in the Regulatory Biology Laboratory at the ... discovery points to an “off switch” for drug resistance in ... her local research is making a global impact in the ... then join host Cheryl K. Goodman, CEO of Social Global ...
(Date:11/18/2014)... Array Architects is proud of a 30-year ... nation's hospitals and health systems. It is a niche ... careers to the advancement of both the healthcare and ... field, Laura Silvoy has been chosen to share her ... Conference. , Laura will present her Process Simulation ...
(Date:11/17/2014)... The new METTLER TOLEDO White Paper ... challenges of becoming the first calibration laboratory in ... weights in the microgram range. National Metrology Institutes ... scientists involved in nanotechnology applications will benefit from ... calibration of weights in the range of 0.05 ...
Breaking Biology Technology:Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3Array Healthcare Simulation Expert Slated to Speak at Winter Simulation Conference 2New White Paper on Microgram Weights Describes How to Achieve Traceable Measurement Down to 0.05 Milligrams 2
... Inc. (NASDAQ: NBIX ) today announced its financial results ... the third quarter of 2011, the Company reported net income of ... net income of $3.3 million, or $0.06 per fully diluted share ... ended September 30, 2011, the Company reported a net income of ...
... I: High Blood Pressure , aka Hypertension ... expensive, and mostly ineffective.   Fortunately , ... by natural methods that are both effective, inexpensive, and risk free. ... can help reduce   Chronic Heart/Cardiovascular Disease patients, ...
... Oct. 31, 2011 iBio, Inc. (NYSE ... issuance from the United States Patent and Trademark Office ... Genes in Plants," that further extends iBio,s patent coverage ... technology owned by iBio was developed by scientists at ...
Cached Biology Technology:Neurocrine Biosciences Reports Third Quarter 2011 Results 2Neurocrine Biosciences Reports Third Quarter 2011 Results 3Neurocrine Biosciences Reports Third Quarter 2011 Results 4Neurocrine Biosciences Reports Third Quarter 2011 Results 5Neurocrine Biosciences Reports Third Quarter 2011 Results 6Neurocrine Biosciences Reports Third Quarter 2011 Results 7Neurocrine Biosciences Reports Third Quarter 2011 Results 8Drug-Free BLOOD PRESSURE Control & Medical "Take-Away" Treatment are Potential Win-Win Solutions in Health Care 2iBio Announces New US Patent for iBioLaunch™ Technology 2iBio Announces New US Patent for iBioLaunch™ Technology 3
(Date:11/4/2014)... majority of Madagascar,s 101 species of lemurs are threatened ... the rainforests they call home. A new study by ... have on rainforest tree populations, which raises concerns about ... region,s rich biodiversity. , A large proportion of trees ... Lemurs in turn disperse the seeds of their fruit ...
(Date:11/3/2014)... , Nov. 3, 2014 Research and ... "Cell Therapy - Technologies, Markets and Companies" to ... cell therapy technologies and methods, which have already started to ... stem cell transplantation is replacing the old fashioned bone marrow ... Cell therapy is bound to become a part of medical ...
(Date:11/3/2014)... Nov. 3, 2014  NeuroSigma ® , Inc. ... sciences company focused on commercialization of its non-invasive ... the treatment of neurological and neuropsychiatric disorders, announced ... has issued a Notice of Allowance for Mexican ... co-owned by NeuroSigma and the Regents of the ...
Breaking Biology News(10 mins):Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... DCMay 28, 2008A 2008 American Society for Microbiology (ASM) ... to Marvin Whiteley, Assistant Professor, Molecular Genetics and Microbiology, ... Laboratories, the Merck Irving S. Sigal Memorial Award is ... instrumental in the early discovery of therapies to treat ...
... German . The sense of smell might ... fish or even mammals. This is the main conclusion of ... and her colleagues. The sense of smell in birds was, ... studies have shown that some bird species use their sense ...
... "Leatherback Turtle" you might think the sea turtles could stand ... them, and for more than a hundred million years, they ... of leatherbacks in the eastern Pacific Ocean has plummeted by ... many species that migrate across a vast ocean, pinpointing all ...
Cached Biology News:Do birds have a good sense of smell? 2Leatherback turtles' newly discovered migration route may be roadmap to salvation 2Leatherback turtles' newly discovered migration route may be roadmap to salvation 3Leatherback turtles' newly discovered migration route may be roadmap to salvation 4Leatherback turtles' newly discovered migration route may be roadmap to salvation 5Leatherback turtles' newly discovered migration route may be roadmap to salvation 6
Request Info...
... 5B15-5B-11E. Immunogen: Synthetic peptide derived from ... protein. Specificity: Specific for the ... Western blots it identifies the target band ... (positive controls: deglycosylated secreted media from primary ...
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
Prepared with distilled water. Yeast extract solution is autolyzed at 150 g/L....
Biology Products: